Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Alfa eCare in connection with the acquisition of Avancit AB
Mandate

Vinge advises Main Capital and Alfa eCare in connection with the acquisition of Avancit AB

September 08, 2022 Employment and Benefits M&A Real Estate and Construction IT, Telecommunications and Outsourcing

The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.

Avancit AB is a leading market player in Sweden within business-developing software solutions for personal assistance providers. The company offers services to both smaller and larger companies within several areas of expertise - including system development, implementation, support, training and infrastructure. The acquisition of Avancit AB is the fifth acquisition by the Alfa eCare group since Main Capital became majority owners of the group in 2020.

Vinge’s team advising Main Capital and Alfa eCare consisted of Jonas Johansson, Filip Öhrner, Per Kling, Linus Adolfsson, Sophie Böje, Jonna Skog, Sara Strandberg, Hedvig Ekdahl, Nicklas Thorgerzon and Rebecka Målquist.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025